Phase II Clinical Trial of Concurrent Chemoradiotherapy Combined Nimotuzumab for Stage IIB-IVA Cervical Cancer

Inclusion Criteria:

• 18 Years to 70 Years，female
• Histological diagnosis of squamous cell carcinoma of cervix, FIGO stage IIB-IVA,with diameter 4-6 cm, without distant metastasis.
• no chance of surgery confirmed by more than two deputy chief doctors of gynecology.
• Moderate or high expression of EGFR
• The function of main organ is normal, including blood, heart, lung, liver, and kidney. Without history of hypertension, stroke. Blood pressure is normal before treatment.
• WBC≥3.5×10E9/L，ANC≥1.5×10E9/L；HB≥90g/L，PLT≥100×10E9/L
• ALT, AST and Cr below 1.5 times of normal level
• Willing to accept treatment
• Ability to comply with trial requirements KPS≥70

Exclusion Criteria:

• Evidence of distance metastasis
• Impossible to measure the diameter of tumor, or the tumor is too huge (diameter>6cm)
• Couldn't examine with pelvic MRI due to a variety of reasons
• Used to treat with radiotherapy chemotherapy or molecular target therapy and immune therapy
• Diagnosed with another malignant tumor in 5 years
• Used to be a volunteer of other clinical trial.
• Used to be allergic reaction with grade 3 or 4 degree to any experimental drugs
• Severe medical history of lung ,liver, kidney or heart.
• Active infection in any part of the whole body.
• Examination results showed radiotherapy contraindications